Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C1519176 (
PSA
)
5,490
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Androgen receptor (AR) is a steroid hormone receptor that functions as a transcription factor for regulating cell growth and survival. Aberrant AR function becomes a risk factor for promoting the progression of prostate cancer (PCa). In this study, we examined the roles of
proline-rich tyrosine kinase 2
(
PYK2
) and ribosomal S6 kinase 1 (S6K1) in regulating AR expression and activity and growth properties in PCa cells. Compared with normal prostate tissues, PCa tumors exhibited high levels of
PYK2
and S6K1 expression. Furthermore, the expression levels of
PYK2
and S6K1 were significantly correlated with nuclear AR expression in PCa tissues. We further found the association between
PYK2
, S6K1, and AR in their protein expression and phosphorylation levels among normal prostate PZ-HPV-7 cells and prostate cancer LNCaP and 22Rv1 cells. Overexpression of the wild-type
PYK2
in PZ-HPV-7 and LNCaP cells promoted AR and S6K1 expression and phosphorylation as well as enhanced cell growth. In contrast, expression of the mutated
PYK2
or knockdown of
PYK2
expression in LNCaP or 22Rv1 cells caused reduced expression or phosphorylation of AR and S6K1 as well as retarded cell growth. Under an androgen-deprived condition,
PYK2
-promoted AR expression and phosphorylation and
PSA
production in LNCaP cells can be abolished by knocking down S6K1 expression. In summary, our data suggested that
PYK2
via S6K1 activation modulated AR function and growth properties in PCa cells. Thus,
PYK2
and S6K1 may potentially serve as therapeutic targets for PCa treatment.
...
PMID:PYK2 via S6K1 regulates the function of androgen receptors and the growth of prostate cancer cells. 2749 35